查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2048123

細胞治療市場－全球產業規模、佔有率、趨勢、機會和預測：按治療類型、治療領域、地區和競爭格局分類，2021-2031年

Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type, By Therapeutic Area, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞治療市場預計將從 2025 年的 67.4 億美元大幅成長至 2031 年的 133.2 億美元，複合年成長率為 12.02%。

細胞療法透過將活性細胞輸注給患者以修復或替換受損組織，從而治療多種疾病，其作用是推動細胞療法發展的主要因素。癌症和自體免疫疾病等慢性疾病的日益普遍是關鍵促進因素。這些因素，加上生物製程和基因編輯技術的進步加速了臨床應用，共同推動了對創新治療方法的需求。根據美國細胞與基因治療學會（ASGCT）統計，到2025年，全球在研計畫將超過3,200項，顯示該領域正持續活躍發展。

市場概覽
預測期 2027-2031
市場規模：2025年 67.4億美元
市場規模：2031年 133.2億美元
複合年成長率：2026-2031年 12.02%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

儘管前景可期，但不斷飆升的生產和治療成本對市場成長構成了重大挑戰。個人化療法生產相關的複雜物流要求推高了價格，加重了醫療系統的負擔，並限制了病患的就醫途徑。因此，從保險公司獲得足夠的報銷是這些先進治療方法廣泛商業化和應用的主要障礙。

市場促進因素

全球慢性病和癌症盛行率的上升是細胞治療市場的主要驅動力，也因此迫切需要CAR-T和TCR療法等突破性治療方法。隨著複雜疾病日益普遍，醫療系統正逐漸從單純的症狀管理轉向為那些對傳統生物製藥無反應的疾病引入先進的細胞療法。這一趨勢在腫瘤學領域尤其顯著，不斷成長的患者數量使得這些關鍵治療方法的廣泛應用勢在必行。美國癌症協會發布的《2025年癌症事實與數據》（2025年1月）預測，美國將新增2,041,910例癌症病例，凸顯了應對這一日益嚴峻的健康危機，迫切需要創新的治療方法。

同時，臨床試驗的多樣化和監管核准的加速推動了市場發展，細胞療法的應用範圍從血液系統惡性腫瘤擴展到固體癌和自體免疫疾病。大規模的研發投入和有利的法規核准為這項創新提供了支持，加速了突破性療法進入市場。根據美國基因與細胞治療學會 (ASGCT) 發布的《2024 年第三季基因、細胞和 RNA 療法趨勢報告》（2024 年 10 月），2024 年第三季啟動的新基因療法試驗中有 51% 針對非腫瘤性疾病，凸顯了這些技術治療範圍的不斷擴大。整體研發規模也進一步支撐了這一成長。根據 InGeNA 發布的《2024 年第三季全球基因、細胞和 RNA 療法趨勢更新報告》（2024 年 12 月），全球治療產品線已相當成熟，目前包含 4000 多種獨特的治療方法，可滿足廣泛的未滿足醫療需求。

市場挑戰

細胞療法生產和治療的高昂成本嚴重阻礙了全球細胞療法市場的商業性擴張。這些個人化療法的生產需要複雜且勞力密集的物流流程，導致銷貨成本遠高於傳統藥品。這些營運成本最終會轉嫁到醫療系統，保險公司往往出於預算考量而延遲或限制賠償。因此，即使是臨床有效的治療方法也難以快速進入市場，而漫長的報銷談判也限制了嚴重患者獲得治療的機會。

這些財務限制直接阻礙了整體市場擴張，因為經濟效益集中在少數幾種成熟治療方法上，而非促進更廣泛的治療產品線發展。價格壓力限制了患者的可及性，導致患者數量偏低，並阻礙了規模經濟的實現，而規模經濟本來可以降低未來的生產成本。再生醫學聯盟在2025年報告中指出，全球銷售高度集中，約75%的產業總銷售額來自不到10種市售產品。這種差異清楚地表明，市場准入壁壘是如何有效地阻礙細胞治療領域的成長潛力的。

市場趨勢

異體「即用型」治療平台的快速發展正在改變市場格局，緩解了自體治療在物流和財務方面的限制。與需要複雜耗時的血球分離術和個人化處理的患者特異性治療不同，異體治療利用健康捐贈者的細胞，生產可立即使用且可規模化生產的批次。這項創新不僅降低了生產成本，還顯著縮短了治療前置作業時間，這對病情快速進展的患者至關重要。這種方法的臨床療效在固體癌治療領域日益凸顯，而實體腫瘤一直是細胞治療的挑戰所在。根據Allogene Therapeutics公司於2024年11月發布的2024年第三季財報，ALLO-316的I期TRAVERSE試驗顯示，在CD70陽性腎細胞癌患者中，總緩解率達到50%，證明了異體移植平台在血液系統惡性腫瘤以外的領域也具有強大的療效。

同時，自動化和封閉式系統製造技術的廣泛應用正逐步成為消除生產瓶頸的標準操作方法。生物製藥公司正從勞動密集、污染風險高的開放式手動製程轉向全自動平台，以確保產品品質的穩定性並提高生產效率。這項技術進步對於滿足商業性需求、降低銷貨成本以及最終擴大市場覆蓋範圍至關重要。該行業為實現這一轉型所做的努力體現在對先進生產基礎設施的大量投資上。例如，2024年4月，百時美施貴寶公司在一份題為「百時美施貴寶與Cellares宣布達成3.8億美元全球產能保障和供應協議」的聲明中宣布，將投資高達3.8億美元以確保獲得自動化細胞療法生產產能的獨家使用權，這凸顯了該行業向高通量、封閉式系統生產模式的戰略戰略。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞療法市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療類型（自體移植、異體移植）
    • 依治療領域（腫瘤科、心血管疾病科、肌肉骨骼系統疾病科、皮膚科）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲細胞療法市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球細胞治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17182

The global cell therapy market is projected to expand significantly, from USD 6.74 billion in 2025 to USD 13.32 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 12.02%. This growth is underpinned by cell therapy's role in delivering viable cells to patients for repairing or replacing damaged tissues, addressing various diseases. Key drivers include the increasing incidence of chronic conditions like cancer and autoimmune disorders, which fuels the demand for innovative treatments, alongside advancements in bioprocessing and gene editing that expedite their clinical application. In 2025, the global pipeline featured over 3,200 trials, as reported by the American Society of Gene & Cell Therapy, indicating robust ongoing development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.74 Billion
Market Size 2031USD 13.32 Billion
CAGR 2026-203112.02%
Fastest Growing SegmentOncology
Largest MarketNorth America

Despite this promising outlook, market growth faces substantial challenges due to the elevated manufacturing and treatment costs. The intricate logistical demands of producing personalized therapies lead to high prices, burdening healthcare systems and limiting patient access. Consequently, obtaining sufficient reimbursement from insurance providers is a crucial obstacle hindering the broad commercialization and adoption of these advanced therapies.

Market Driver

The increasing worldwide prevalence of chronic and oncological conditions is the primary driver for the cell therapy market, generating an urgent need for transformative treatments such as CAR-T and TCR therapies. As complex diseases become more common, healthcare systems are increasingly shifting from merely managing symptoms to deploying advanced cellular medicines for conditions unresponsive to traditional biologics. This trend is especially pronounced in oncology, where the rising patient load mandates the widespread adoption of these crucial interventions. The American Cancer Society's 'Cancer Facts & Figures 2025' (January 2025) projects 2,041,910 new cancer cases in the United States, highlighting the critical demand for innovative therapeutic approaches to this growing health crisis.

Concurrently, the market is boosted by an expanding array of clinical trials and accelerated regulatory approvals, which are broadening the application of cell therapies beyond blood cancers to include solid tumors and autoimmune diseases. This innovation is supported by substantial development efforts and advantageous regulatory designations that speed up the market entry of groundbreaking treatments. The 'Q3 2024 Gene, Cell, + RNA Therapy Landscape Report' from the American Society of Gene & Cell Therapy (October 2024) indicates that 51% of new gene therapy trials initiated in Q3 2024 focused on non-oncology conditions, underscoring the expanding therapeutic scope of these technologies. The overall scale of development further supports this growth; InGeNA's 'Global Gene, Cell, and RNA Therapy Trends - Q3 2024 Update' (December 2024) notes that the global therapy pipeline has significantly matured, now comprising over 4,000 unique treatments addressing a wide range of unmet medical needs.

Market Challenge

The significant costs involved in manufacturing and treating patients with cell therapies present a major barrier to the commercial expansion of the global cell therapy market. The production of these personalized treatments demands complex, labor-intensive logistical processes, resulting in substantially higher costs of goods sold compared to traditional medicines. These operational expenditures are passed onto healthcare systems, often causing insurance providers to delay or restrict coverage to manage their budgets. As a result, even clinically effective therapies face difficulties in achieving swift market entry, with prolonged reimbursement negotiations limiting patient access to only the most critical cases.

This financial constraint directly hinders the broader market by concentrating financial success among a select few established treatments, rather than fostering the growth of the wider therapeutic pipeline. When access is limited by pricing pressures, the number of patients receiving treatment stays low, preventing the realization of economies of scale that could otherwise reduce future production expenses. The Alliance for Regenerative Medicine reported in 2025 that global revenue was highly concentrated, with roughly 75 percent of the sector's total revenue generated by fewer than 10 commercial products. This disparity clearly demonstrates how market access obstacles effectively impede the growth potential across the broader cell therapy landscape.

Market Trends

The rapid development of allogeneic "off-the-shelf" therapy platforms is transforming the market by mitigating the logistical and financial constraints associated with autologous treatments. In contrast to patient-specific therapies, which involve complex, time-consuming apheresis and individualized processing, allogeneic options use healthy donor cells to produce scalable batches ready for immediate use. This innovation not only lowers manufacturing expenses but also significantly shortens the treatment turnaround time, which is vital for patients with fast-advancing diseases. The clinical effectiveness of this method is increasingly apparent in solid tumor applications, a historically challenging area for cellular medicines. As reported by Allogene Therapeutics in their November 2024 'Third Quarter 2024 Financial Results', the Phase 1 TRAVERSE trial for ALLO-316 showed a 50% overall response rate in patients with CD70-positive renal cell carcinoma, confirming the capability of allogeneic platforms to achieve strong efficacy beyond blood cancers.

Concurrently, the widespread implementation of automated and closed-system manufacturing technologies is emerging as a standard operational approach to resolve production bottlenecks. Biopharmaceutical companies are moving away from manual, open-process methods, which are labor-intensive and susceptible to contamination, in favor of fully automated platforms that guarantee consistent product quality and increased throughput. This technological advancement is crucial for meeting commercial demand and reducing the cost of goods sold, thereby expanding market accessibility. The industry's dedication to this shift is highlighted by significant investments in advanced production infrastructure. For instance, Bristol Myers Squibb, in April 2024, committed up to $380 million to secure exclusive access to automated cell therapy manufacturing capacity, as stated in their 'Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement', emphasizing the sector's strategic move toward high-throughput, closed-system production models.

Key Market Players

  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • Tego Science
  • Atara Biotherapeutics
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio, Inc.
  • Dendreon Corp.

Report Scope

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Therapy Market, By Therapy Type

  • Autologous
  • Allogenic

Cell Therapy Market, By Therapeutic Area

  • Oncology
  • Cardiovascular Diseases
  • Musculoskeletal Disorders
  • Dermatology

Cell Therapy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

Global Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Autologous, Allogenic)
    • 5.2.2. By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cell Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By Therapeutic Area
    • 6.3.2. Canada Cell Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By Therapeutic Area
    • 6.3.3. Mexico Cell Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By Therapeutic Area

7. Europe Cell Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By Therapeutic Area
    • 7.3.2. France Cell Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By Therapeutic Area
    • 7.3.3. United Kingdom Cell Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By Therapeutic Area
    • 7.3.4. Italy Cell Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By Therapeutic Area
    • 7.3.5. Spain Cell Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Cell Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By Therapeutic Area
    • 8.3.2. India Cell Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By Therapeutic Area
    • 8.3.3. Japan Cell Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By Therapeutic Area
    • 8.3.4. South Korea Cell Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By Therapeutic Area
    • 8.3.5. Australia Cell Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Cell Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By Therapeutic Area
    • 9.3.2. UAE Cell Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By Therapeutic Area
    • 9.3.3. South Africa Cell Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By Therapeutic Area

10. South America Cell Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By Therapeutic Area
    • 10.3.2. Colombia Cell Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By Therapeutic Area
    • 10.3.3. Argentina Cell Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Gilead Sciences, Inc.
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Johnson & Johnson Services, Inc
  • 15.5. JCR Pharmaceuticals Co., Ltd.
  • 15.6. Tego Science
  • 15.7. Atara Biotherapeutics
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. Bluebird Bio, Inc.
  • 15.10. Dendreon Corp.

16. Strategic Recommendations

17. About Us & Disclaimer